ClinicalTrials.gg
CompletedNCT00971945Updated May 25, 2021Results posted

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer

A Phase 2 interventional study of Paclitaxel in Breast Cancer, sponsored by Bristol-Myers Squibb. Completed at 4 sites in Japan. Open to female participants. Per ClinicalTrials.gov, last updated 2021-05-25.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 2 months after the study started (first participant enrolled Jun 2005, registered Sep 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Enrollment
345th of 361
6 · median 60
Started
2005
with 16 others
Phase 2
205 of 373
20 open now
Registered
165th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 345th largest by enrollment of the 361 interventional ones that give a count, is one of 17 that started in 2005, is one of 205 in phase 2, and was the 165th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of continued administration of paclitaxel given weekly in subjects considered to need to continue treatment after completion of the preceding "Phase II Clinical Study of Weekly Paclitaxel (BMS-181339) with Advanced Breast Cancer (Protocol No. CA139-371)"

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Paclitaxel

    Drug: Paclitaxel

Interventions

  • Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent

    Also known as: Taxol, BMS-181339

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events

    This outcome describes the number of participants experiencing any type, any grade, any cause adverse events (assessed both subjectively and objectively)

    Time frame: From first dose to end of follow-up period (up to approximately 33 months)

  2. Number of Participants Experiencing Laboratory Tests Abnormalities

    This outcome describes the number of participants experiencing laboratory test abnormalities. The following laboratory test categories were analyzed: * Enzyme investigations * Hematology investigations * Hepatobiliary investigations * Lipid investigations * Protein and chemistry analyses * Renal and urinary tract investigations * Water, electrolytes and mineral investigation. Laboratory test abnormalities were graded according to the NCI Common Toxicity Criteria version 2 (JCOG Version), resulting in a score from Grade 0 (Normal) to Grade 5 (Death due to toxicity). Only laboratory test abnormalities with a Grade 3 or higher are reported

    Time frame: From first dose to end of follow-up period (up to approximately 33 months)

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the number (percentage) of participants achieving either a Complete Response (CR) or Partial Response (PR) to therapy. CR is defined as disappearance of all target lesions, while PR is defined as at least a 30% decrease in the sum of longest diameter (LD) of all target lesions (taking as reference the baseline sum LD). Target Lesions were evaluated according to "Evaluation Criteria on the Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer."

    Time frame: From first dose to end of follow-up period (up to approximately 33 months)

  2. Duration of Response (DOR)

    DOR is defined as the median time from the first date of Partial Response (assessed as per the "Evaluation Criteria on the Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer") to the first date of Progressive Disease. Participants were evaluated for DOR in 2 separate studies (NCT01023204 and NCT00971945). Results are representative of the cumulative DOR assessed in both studies.

    Time frame: From first date of Partial Response (in study NCT01023204) to first date of Progressive Disease (in study NCT01023204 or NCT00971945) (up to approximately 37 months)

07

Results

Posted May 25, 2021

Participant flow

Participant flow — Overall Study
MilestoneTreatment Arm
Started6
Completed0
Not completed6
Withdrew: Progressive disease3
Withdrew: Change in treatment policy1
Withdrew: Other reasons2

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events

This outcome describes the number of participants experiencing any type, any grade, any cause adverse events (assessed both subjectively and objectively)

Time frame:
From first dose to end of follow-up period (up to approximately 33 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsTreatment Arm
Number of Participants Experiencing Adverse Events6
PrimaryNumber of Participants Experiencing Laboratory Tests Abnormalities

This outcome describes the number of participants experiencing laboratory test abnormalities. The following laboratory test categories were analyzed: * Enzyme investigations * Hematology investigations * Hepatobiliary investigations * Lipid investigations * Protein and chemistry analyses * Renal and urinary tract investigations * Water, electrolytes and mineral investigation. Laboratory test abnormalities were graded according to the NCI Common Toxicity Criteria version 2 (JCOG Version), resulting in a score from Grade 0 (Normal) to Grade 5 (Death due to toxicity). Only laboratory test abnormalities with a Grade 3 or higher are reported

Time frame:
From first dose to end of follow-up period (up to approximately 33 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Tests Abnormalities
ParticipantsTreatment Arm
Hematology investigations1
Lipid analyses1
SecondaryOverall Response Rate (ORR)

ORR is defined as the number (percentage) of participants achieving either a Complete Response (CR) or Partial Response (PR) to therapy. CR is defined as disappearance of all target lesions, while PR is defined as at least a 30% decrease in the sum of longest diameter (LD) of all target lesions (taking as reference the baseline sum LD). Target Lesions were evaluated according to "Evaluation Criteria on the Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer."

Time frame:
From first dose to end of follow-up period (up to approximately 33 months)
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsTreatment Arm
Overall Response Rate (ORR)5
SecondaryDuration of Response (DOR)

DOR is defined as the median time from the first date of Partial Response (assessed as per the "Evaluation Criteria on the Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer") to the first date of Progressive Disease. Participants were evaluated for DOR in 2 separate studies (NCT01023204 and NCT00971945). Results are representative of the cumulative DOR assessed in both studies.

Time frame:
From first date of Partial Response (in study NCT01023204) to first date of Progressive Disease (in study NCT01023204 or NCT00971945) (up to approximately 37 months)
Reported as:
Median · Days
Duration of Response (DOR)
DaysTreatment Arm
Duration of Response (DOR)840 (229 to 1156)

Adverse events

Collected over From first dose to 14 days following last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm0/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment Arm
NauseaGastrointestinal disorders1/6
VomitingGastrointestinal disorders1/6
Femur fractureInjury, poisoning and procedural complications1/6
Most frequent other events
Showing 10 of 66
Most frequent other events
EventTreatment Arm
HypoaesthesiaNervous system disorders6/6
AlopeciaSkin and subcutaneous tissue disorders6/6
OedemaGeneral disorders5/6
FatigueGeneral disorders4/6
NasopharyngitisInfections and infestations4/6
MyalgiaMusculoskeletal and connective tissue disorders4/6
Nail disorderSkin and subcutaneous tissue disorders4/6
ConstipationGastrointestinal disorders3/6
StomatitisGastrointestinal disorders3/6
Weight increasedInvestigations3/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment Arm
Median46.0 (33 to 53)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm
Female6
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Arm
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Local Institution
    Nagoya, Aichi 464-8681, Japan
  • Local Institution
    Hiroshima-shi, Hiroshima 731-0293, Japan
  • Local Institution
    Kagoshima-shi, Kagoshima 892-0833, Japan
  • Local Institution
    Toshima-ku, Tokyo 170-8455, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2005 to primary completion in Mar 2008, 33 months.

Results were first posted in May 2021, 13 years 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 33 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2009
First posted
Sep 4, 2009
StartActual
Jun 30, 2005
Primary completionActual
Mar 31, 2008
CompletionActual
Mar 31, 2008
Results first posted
May 25, 2021
Last update
May 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00971945
Responsible party
Sponsor
First posted
Sep 4, 2009
Start date
Jun 30, 2005
Primary completion
Mar 31, 2008
Completion
Mar 31, 2008
Results posted
May 25, 2021
Last update
May 25, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion